Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R 20 —(Z) b —(Y) c —(R 21 ) a —(X) d —R 22 —R 23 wherein R 20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, S(═O), —S(═O)(═O)—, or NR 10 , wherein R 10 is H or alkyl; R 21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; X is —C(═O)—, —S(═O)(═O)—, or —N(H)C(═O)—; R 22 includes at least one divalent amino radical; R 23 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; a, b, c, and d independently are 0 or 1.
1. A method for treating prostate cancer in a subject, comprising administering to the subject a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or ester thereof, selected from:
2. The method of claim 1 , wherein the compound is:
3. The method of claim 1 , wherein the compound is:
4. The method of claim 1 , wherein the compound is:
5. The method of claim 1 , wherein the compound is:
6. The method of claim 1 , wherein administering a therapeutically effective amount of the compound comprises administering a pharmaceutical composition comprising the therapeutically effective amount of the compound and at least one pharmaceutically acceptable additive.
7. The method of claim 1 , wherein the prostate cancer is castration-resistant prostate cancer.
8. The method of claim 1 , wherein the compound is orally administered.
9. The method of claim 1 , wherein the method is used in combination with androgen deprivation therapy.
10. The method of claim 1 , wherein the agent is co-administered with abiraterone.
11. The method of claim 1 , wherein the agent is co-administered with enzalutamide.
12. The method of claim 1 , wherein the method further comprises identifying a subject that is in need of treatment with the agent.
13. The method of claim 1 , wherein the therapeutically effective amount of the compound is from about 0.01 mg/kg body weight to about 20 mg/kg body weight.
14. The method of claim 1 , wherein administering the therapeutically effective amount of the compound reduces a nuclear level of androgen receptor in castration-resistant prostate cancer (CRPC) cells relative to untreated CRPC cells.
15. The method of claim 14 , wherein reducing the nuclear level of androgen receptor inhibits activation of the androgen receptor.
16. The method of claim 15 , wherein a reduction in androgen receptor activation is determined by measuring prostate-specific antigen.